← Back to Search

Cervical Cancer Prevention Program for Muslim Women

N/A
Waitlist Available
Research Sponsored by Mark Dignan, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and post intervention (up to 1 week)
Awards & highlights
No Placebo-Only Group

Summary

This trial will develop and evaluate an intervention program to help Muslim American women learn about and accept cervical cancer prevention.

Eligible Conditions
  • Human Papillomavirus
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and post intervention (up to 1 week)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and post intervention (up to 1 week) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Women Who Undergo Cervical Cancer Screening.
Secondary study objectives
Number of Women Enrolled
Other study objectives
Number of Women That Attend the Education Session

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: The single-arm trial with a pre- and post-test designExperimental Treatment1 Intervention
The Intervention Arm in the Promise Women Project evaluates a specific educational intervention program for Muslim women to promote cervical cancer prevention. It involves a one-time, 90-minute culturally and religiously tailored educational session with 20 participants. The session covers perceived risks of Human Papilloma Virus (HPV) infection, cervical cancer, and benefits of early screening and vaccination. Pre- and post-intervention surveys measure changes in participants' knowledge. This experimental arm assesses the intervention's effects on knowledge and acceptance of cervical cancer prevention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )
2023
N/A
~20

Find a Location

Who is running the clinical trial?

Mark Dignan, PhDLead Sponsor
1 Previous Clinical Trials
669 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,560 Total Patients Enrolled
Virginia Commonwealth UniversityOTHER
719 Previous Clinical Trials
22,895,816 Total Patients Enrolled
Vanessa L Sheppard, PhDStudy DirectorVirginia Commonwealth University
Mark B Dignan, PhD, MPHStudy DirectorUniversity of Kentucky

Media Library

The single-arm trial with a pre- and post-test design Clinical Trial Eligibility Overview. Trial Name: NCT05862844 — N/A
Human Papillomavirus Research Study Groups: The single-arm trial with a pre- and post-test design
Human Papillomavirus Clinical Trial 2023: The single-arm trial with a pre- and post-test design Highlights & Side Effects. Trial Name: NCT05862844 — N/A
The single-arm trial with a pre- and post-test design 2023 Treatment Timeline for Medical Study. Trial Name: NCT05862844 — N/A
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top